ABBV vs AVGO: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Broadcom Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-24.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Broadcom Inc. · Technology
$354.99
+15.1% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
AVGO has more upside to fair value
(+15.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
AVGO |
| Current Price |
$261.70 |
$354.99 |
| Fair Value Estimate |
$259.04 |
$408.70 |
| Upside to Fair Value |
-1.0%
|
+15.1%
|
| Market Cap |
$462.4B |
$1,688.9B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
33.0x
|
| Price / Sales |
7.2x
|
18.9x
|
| Price / FCF |
23.6x
|
42.9x
|
| Revenue Growth YoY |
+10.2%
|
+85.5%
|
| Gross Margin |
71.5%
|
67.7%
|
| Operating Margin |
29.3%
|
48.3%
|
| Return on Equity |
-136.5%
|
43.9%
|
| Dividend Yield |
2.61% |
0.73% |
| FCF Yield |
4.25%
|
2.33%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Broadcom is a diversified semiconductor and infrastructure software company led by CEO Hock Tan, with a portfolio spanning custom AI ASICs, networking, wireless, storage, and enterprise software. The business quality is high: TTM gross margin of 67.7%, TTM operating margin of 48.3%, TTM net margin of 42.9%, and ROE of 43.9% demonstrate exceptional profitability, while revenue growth of 85.5% and …
Accumulation Zones
| Metric |
ABBV |
AVGO |
| Zone Low |
$194.28 |
$306.52 |
| Zone High |
$220.18 |
$347.39 |
| In Buy Zone? |
No
|
No
|